Use of Focalin for Fatigue in Sarcoidosis
NCT00361387 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2011-02-24
Summary
Patients diagnosed with chronic sarcoidosis with fatigue for more than 6 months. Sarcoidosis and its treatment can greatly affect your quality of life. Many patients suffer from fatigue (feeling tired), lack of focus and concentration, in ability to organize their daily activities, and memory loss. These commonly reported symptoms often get in the way of everyday life.
Conditions
- Sarcoidosis
Interventions
- DRUG
-
d-methylphenidate
oral dosing for 8 weeks then cross over to placebo in random order
Sponsors & Collaborators
-
University of Cincinnati
lead OTHER
Principal Investigators
-
Robert P Baughman, MD · Unversity of Cincinnati
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-06-30
- Primary Completion
- 2007-06-30
- Completion
- 2008-01-31
Countries
- United States
Study Locations
More Related Trials
-
Treatment of CNS Sarcoidosis With H.P. Acthar Gel
NCT02298491 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT03485547 ·Status: COMPLETED ·Phase: PHASE1
-
Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis
NCT00695643 ·Status: TERMINATED ·Phase: PHASE3
-
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
NCT03935555 ·Status: TERMINATED ·Phase: PHASE1
-
Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis
NCT03793439 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib
NCT05665192 ·Status: COMPLETED
-
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib
NCT01523171 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis
NCT07012057 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis
NCT05314517 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Infliximab in Patients With Sarcoidosis
NCT00073437 ·Status: COMPLETED ·Phase: PHASE3
-
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
NCT00282438 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
NCT03616184 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
NCT03373877 ·Status: TERMINATED ·Phase: PHASE1
-
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
NCT06019728 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis
NCT05351554 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
NCT03320707 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
NCT06730126 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
NCT00005571 ·Status: COMPLETED ·Phase: PHASE2
-
Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis
NCT01732445 ·Status: COMPLETED ·Phase: PHASE2
-
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
NCT04681729 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
NCT03770273 ·Status: COMPLETED ·Phase: PHASE2
-
Pathogen Specific Immunity in Patients With Sarcoidosis
NCT00217789 ·Status: COMPLETED
-
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
NCT04008069 ·Status: COMPLETED ·Phase: PHASE2
-
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
NCT05334368 ·Status: RECRUITING ·Phase: PHASE3
-
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
NCT06780332 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4